Trials / Completed
CompletedNCT03525665
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 175 (actual)
- Sponsor
- Fondazione Italiana Linfomi - ETS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.
Detailed description
The study does not require any intervention on the patient, but it involves the simple collection of data that are already present in the medical record. Since this is a retrospective study, it will not require further analysis or diagnostic investigations than those already made.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Metabolic activity measured by FDG-PET | To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome. |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2019-12-30
- Completion
- 2019-12-30
- First posted
- 2018-05-16
- Last updated
- 2020-02-06
Locations
27 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT03525665. Inclusion in this directory is not an endorsement.